Oncolytics Biotech released promising results Thursday from its Phase I/II GOBLET study in advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) that support plans to advance the program into Phase III.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,